Acadia Pharmaceuticals Inc (ACAD) valuation
Acadia Pharmaceuticals P/E ratio history
Acadia Pharmaceuticals trades at 9.2 times its earnings over the last twelve months and 27.2 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $26.71 | $2.30 | 11.6 | 35.5 |
| Dec 31, 2024 | $18.35 | $1.36 | 13.5 | 23.8 |
| Dec 31, 2023 | $31.31 | -$0.38 | n/m | — |
| Dec 31, 2022 | $15.92 | -$1.34 | n/m | — |
| Dec 31, 2021 | $23.34 | -$1.05 | n/m | — |
| Dec 31, 2020 | $53.46 | -$1.80 | n/m | — |
| Dec 31, 2019 | $42.78 | -$1.60 | n/m | — |
| Dec 31, 2018 | $16.17 | -$1.95 | n/m | — |
| Dec 31, 2017 | $30.11 | -$2.35 | n/m | — |
| Dec 31, 2016 | $28.84 | -$2.34 | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Acadia Pharmaceuticals valuation against its peers
| Company | Market value | P/E | Price / sales |
|---|---|---|---|
| Acadia PharmaceuticalsACAD | $3.53B | 9.2 | 3.1 |
| Relay TherapeuticsRLAY | $3.52B | — | 339.7 |
| Pulse BiosciencesPLSE | $3.62B | — | — |
| Xenon PharmaceuticalsXENE | $3.62B | — | — |
| CelcuityCELC | $3.37B | — | — |
| Tango TherapeuticsTNGX | $3.29B | — | 61.1 |
| Iovance BiotherapeuticsIOVA | $3.79B | — | 11.7 |
| National HealthcareNHC | $3.22B | 23.2 | 2.1 |
| Tarsus PharmaceuticalsTARS | $3.22B | — | 5.3 |
| Peer median | 23.2 | 11.7 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: ACAD financials · ACAD returns
No forecast, no recommendation. This page describes Acadia Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.